ERBB2 and breast carcinoma: Bozepinib was a selective inhibitor of HER2 positive breast cancer cells as we demonstrated by the kinase assay, also verified with immunoblot analysis in the HER2 positive SKBR-3 breast cancer cell line, and in the xenotrasplant of HER 2 positive HT-29 colon cancer cells [25] in nude mice.